News – Page 1050 – Endpoints News

Dalcor taps new CEO Fouzia Laghrissi-Thode as pivotal PhIII looms; Kelly Martin settles in at Novan; Edward Stewart ...

8 years ago

Adynxx drug failed in PhII but it’s going into PhIII anyway; Deerfield leads $50M raise for Sollis

8 years ago

Inventiva raises $44M as it preps for a PhIII NASH program, upcoming IIb readout

8 years ago

After patient deaths, failed partnerships and a stock scandal, Hanmi finally gives up on controversial olmutinib. ...

8 years ago

Penn team spotlights a pilot ovarian cancer trial and survival rates for a personalized cancer vaccine

8 years ago

Retire? Bill Chin’s tried it three times, and he’d rather be working at Frequency Therapeutics

8 years ago

Next-generation sequencing: FDA offers guidance to streamline path to market

8 years ago

As gene editing explodes, a new report from Goldman says Chinese groups are seizing the lead on CRISPR and CAR-T ...

8 years ago

Pfizer launches a gene therapy study for Duchenne MD; Amgen, NEA back real-world drug data software company

8 years ago

FDA launches criminal probe into unauthorized herpes vaccine R&D backed by Peter Thiel

8 years ago

Does the FDA’s ‘breakthrough’ drug program need to be reformed? Harvard skeptics say yes

8 years ago

Former Novo chairman Göran Ando joins the board as Tessa bags $50M in additional funding

8 years ago

Continuing an R&D revamp, GlaxoSmithKline hands off its rare disease unit to Orchard Therapeutics

8 years ago

VC believers back a $41M game plan for Enterprise Therapeutics' new group of respiratory drugs

8 years ago

Vivek Ramaswamy is diving into RNA, launching a new biotech with Arbutus and a team of vets

8 years ago

Bellicum shares surge as FDA lifts a clinical hold on lead cell therapy following a protocol adjustment

8 years ago

Flush with a $164M raise, Cellectis ups its bet on CAR-T and gene editing programs

8 years ago

CymaBay shares soar on trial update; Lonza opens massive Texas facility dedicated to cell, gene therapies; Inovio ...

8 years ago

Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths

8 years ago

Biotech M&A is ripping along now as IPOs surge and venture cash flows. Who's the next big target?

8 years ago

Amgen goes back to Rhode Island to build its first next-gen manufacturing site in the US

8 years ago

Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout

8 years ago

More than 2 years after the ugly roci debacle, Clovis says that the SEC is prepping civil charges

8 years ago

Pfizer’s PhIII kidney cancer study for Inlyta flops as investigators flag a dead end on outcomes

8 years ago

First page Previous page 1047 1048 104910501051 1052 1053 Next page Last page